Suprefort
MetabolicAlso known as: Pancreas Bioregulator, Khavinson Pancreas Peptide, Lys-Glu-Asp-Trp, KEDW
Mechanism
Suprefort is a tetrapeptide bioregulator targeting the pancreas — the organ that produces insulin and digestive enzymes. It works by restoring healthy gene expression in pancreatic cells, potentially improving both insulin secretion (endocrine function) and digestive enzyme production (exocrine function). This makes it relevant for age-related blood sugar control issues, chronic pancreatitis recovery, and supporting overall digestive health. It is one of the most sought-after Khavinson bioregulators for metabolic optimization.
Technical detail
Suprefort (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide bioregulator developed by Khavinson targeting pancreatic acinar cells (exocrine) and islet beta cells (endocrine). Per bioregulation theory: the tetrapeptide interacts with DNA in pancreatic cell nuclei, promoting chromatin decondensation and reactivation of genes suppressed during aging. Proposed effects: (1) Endocrine — normalization of insulin gene (INS) expression and glucose-stimulated insulin secretion (GSIS) from beta cells; improved beta cell mass preservation via reduced apoptosis; (2) Exocrine — restored production of pancreatic lipase, amylase, and trypsinogen; improved acinar cell integrity. In aged rat models: Khavinson group reports improved glucose tolerance and pancreatic enzyme output. The Lys-Glu-Asp motif is shared with Prostamax (Lys-Glu-Asp-Pro), suggesting common chromatin-interaction mechanisms with tissue specificity conferred by the fourth residue.
Effects
ENDOCRINE (Pancreatic): Primary target system. Pancreatic islets contain beta cells (insulin), alpha cells (glucagon), delta cells (somatostatin), and PP cells (pancreatic polypeptide). Beta cell mass naturally declines with aging — estimated 0.5-1% per year after age 30, contributing to age-related glucose intolerance and type 2 diabetes risk. Suprefort targets pancreatic cells to normalize gene expression of key endocrine and exocrine functions. Proposed effects on beta cells: normalization of insulin gene (INS) transcription, improved glucose-stimulated insulin secretion (GSIS) by restoring GLUT2 transporter and glucokinase expression, and reduced beta cell apoptosis. GI (Pancreatic Exocrine): The exocrine pancreas produces ~1.5L/day of digestive enzymes (lipase, amylase, trypsin, chymotrypsin). Exocrine insufficiency causes maldigestion, steatorrhea, and fat-soluble vitamin deficiency. Suprefort may support acinar cell enzyme production and ductal bicarbonate secretion. METABOLIC: Central role — pancreatic function directly determines glucose homeostasis, insulin sensitivity, and digestive efficiency. Improved pancreatic function has cascading effects on body composition, energy levels, and metabolic syndrome risk factors. IMMUNE: Chronic pancreatitis involves immune-mediated destruction of pancreatic tissue. Bioregulatory modulation of inflammatory gene expression in pancreatic tissue may slow progression. Tier 3: Users report improved fasting glucose, reduced post-meal blood sugar spikes, better digestion (especially fat digestion), and improved HbA1c levels. Often combined with metabolic peptides (MOTS-c, 5-Amino-1MQ) and digestive support. Popular among biohackers tracking continuous glucose monitors (CGMs) who report smoother glucose curves.
Practitioner Guide
DOSING TIPS: Standard protocol: 1-2 capsules daily for 10-30 days, repeated every 3-6 months. For metabolic optimization: 2 capsules daily for 30 days. Take with meals. SUPPLEMENT SYNERGIES: Berberine (500mg 2-3x/day with meals) — AMPK activation complementary to pancreatic support. Chromium picolinate (200-400mcg/day) for insulin receptor sensitivity. Digestive enzymes (lipase, protease, amylase blend) during treatment for immediate symptom relief. Pancragen (another Khavinson pancreatic bioregulator — capsule form) for additional support. Alpha-lipoic acid (300-600mg/day) for pancreatic antioxidant support. Cinnamon extract (ceylon, 500mg/day) for insulin sensitization. CYCLING: Standard Khavinson protocol — courses with 3-6 month breaks. CONTRAINDICATION NUANCES: Type 1 diabetes — this cannot replace insulin therapy; beta cell mass is destroyed by autoimmunity. Pancreatic cancer — do not stimulate gene expression in neoplastic tissue. Acute pancreatitis — treat underlying condition first. Patients on insulin or sulfonylureas — monitor for hypoglycemia if beta cell function improves. STORAGE: Room temperature, away from moisture. PATIENT EDUCATION: Your pancreas is your body's sugar-processing factory and digestive enzyme plant. This bioregulator aims to keep both sides of that factory running smoothly. It is not insulin and cannot replace diabetes medication. Best used preventively or for early metabolic optimization. Track results with fasting glucose, HbA1c, fasting insulin, and C-peptide levels.
Research Summary
TIER 1 (Gold Standard): No Western clinical trials specific to Suprefort. TIER 2 (Strong): Khavinson bioregulation theory publications. Khavinson et al. — Tetrapeptide (Lys-Glu-Asp-Trp) interaction with DNA — demonstrating sequence-specific binding (in vitro). Pancreatic beta cell aging and decline well-established (Endocrine Reviews). TIER 3 (Moderate): Khavinson group pancreatic bioregulator publications (Russian journals). Product information from Peptide Bio. Practitioner CGM data showing improved glucose variability. Community reports. KEY FINDINGS: (1) Pancreatic function is a strong target for bioregulation due to progressive age-related decline. (2) The KEDW tetrapeptide has been studied for DNA interaction by Khavinson group. (3) No Western validation. GAPS: Standard Khavinson bioregulator gaps. Specific interaction with beta cell gene promoters not demonstrated in independent studies.